mammaprint.nl

Hoe ernstig is uw borstkanker? | MammaPrint® test bij borstkanker
MammaPrint® is een diagnostische test bij borstkanker, het analyseert nauwkeurig de kenmerken van uw borsttumor en bepaalt hoe ernstig deze is. SYMPHONY | Personalize Your Breast Cancer Treatment | Agendia
Why MammaPrint. MammaPrint Patient Brochures; Questions & Answers; FDA Clearance; Getting Your Symphony Profile; Symphony Providers; Insurance Coverage. Questions & Answers MammaPrint - MammaPrint - everything you need to know about MammaPrint
The MammaPrint result will enable your physician to determine what would be the best kind of treatment for you following your operation. The result of a MammaPrint is ... MammaPrint - Wikipedia, the free encyclopedia
MammaPrint is a diagnostic test used by physicians to assess the risk that a breast tumor will metastasize to other parts of the body. This helps physicians determine ... MammaPrint | Genomic Testing for Breast Cancer Prognosis and ...
MammaPrint Provides Individualized Metastasis Risk Assessment for Your Breast Cancer Patients. MammaPrint is the first and only FDA-cleared IVDMIA breast cancer ... MammaPrint - Recent developments
Together with the MammaPrint test result, this information can be used to determine your treatment. TargetPrint delivers reproducible, quantitative gene expression ... MammaPrint Test - BreastCancer.org - Breast Cancer Treatment ...
The MammaPrint test by Agendia analyzes 70 genes from an early-stage breast cancer tissue sample to figure out if the cancer has a low or high risk of coming back ... MammaPrint - sviluppato da una donna per le donne
Il risultato MammaPrint permettera' al tuo medico di determinare quale sara' la migliore terapia per te, dopo l'operazione.. Il risultato di MammaPrint e' molto ... MammaPrint - Simple Genetics
Description MammaPrint is commercial microarray 1 based prognostic breast cancer gene-expresion 2 profiling test of 70 genes. The MammaPrint test measures the level ... Is FDA Approval of MammaPrint a Big Step in Breast Cancer ...
However, the MammaPrint test is not the first of its kind, nor is it impeccably better than its opponent. It is simply the first to be approved by the FDA.

Agendia BV - Medical Equipment - Deals and Alliances Profile - new company profile report
The company develops and manufactures in vitro diagnostics for cancer detection. Its products include CupPrint, TargetPrint, TheraPrint and MammaPrint. Agendia develops molecular diagnostic procedures based on DNA microarray technology. These tests provide ... ColoPrint aids prediction of colorectal cancer relapse
Drawing on previous experience from the development of MammaPrint (Agendia NV), a similar 70-gene tool designed to help predict breast cancer relapse, the researchers developed ColoPrint to improve relapse risk stratification in stage II colon ...